

**AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.121**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1. **(Currently Amended)** A pharmaceutical composition for treatment of a disorder of the eye comprising an aptamer which binds specifically to a target involved in said disorder, ~~wherein the binding of the aptamer to the target substantially reduces the effect of the target.~~
2. **(Original)** The composition of claim 1, wherein said disorder is a cell proliferation disorder.
3. **(Original)** The composition of claim 1, wherein said disorder is characterized by increased intraocular pressure.
4. **(Original)** The composition of claim 3, wherein said disorder is glaucoma.
5. **(Original)** The composition of claim 1, wherein said disorder is post-surgical scarring.
6. **(Original)** The composition of claim 1, wherein said target is selected from the group consisting of cytokines, growth factors, and cell surface proteins.
7. **(Original)** The composition of claim 6, wherein said target is selected from the group consisting of transforming growth factor beta, platelet-derived growth factor, intracellular adhesion molecule-1, insulin-like growth factor-1, vascular endothelial growth factor, tumor necrosis factor alpha, and integrin alpha 5 beta 3.

8. **(Original)** The composition of claim 6, wherein said target is transforming growth factor beta 1, 2, or 3.
9. **(Original)** The composition of claim 8, wherein said transforming growth factor beta is transforming growth factor beta 2.
10. **(Original)** The composition of claim 6, wherein said target is platelet-derived growth factor.
11. **(Original)** The composition of claim 1, further comprising a non-aptamer pharmaceutical agent.
12. **(Original)** The composition of claim 11, wherein the non-aptamer pharmaceutical agent is selected from the group consisting of an anesthetic agent, an anti-inflammatory agent, an anti-angiogenesis agent, an anti-proliferative agent, an anti-bacterial agent, an anti-viral agent, and an anti-fungal agent.
13. **(Original)** The composition of claim 1, further comprising a second aptamer which binds specifically to a target involved in said disorder, wherein the binding of the second aptamer to the target substantially reduces the effect of the target.
14. **(Original)** The composition of claim 13, wherein the first and second aptamers bind specifically to the same type of target involved in said disorder.
15. **(Original)** The composition of claim 13, wherein the first and second aptamers bind specifically to different types of targets involved in said disorder.

16. **(Original)** The composition of claim 1, wherein the aptamer binds specifically to more than one type of target involved in said disorder.
17. **(Original)** The composition of claim 8, comprising an aptamer selected from the group consisting of SEQ ID NOs 1-14, 21-27, 39-149 and 150.
18. **(Original)** The composition of claim 8, comprising an aptamer selected from the group consisting of ARC77, ARC78, ARC81, and ARC154.
19. **(Original)** The composition of claim 10, comprising an aptamer selected from the group consisting of SEQ ID NOs 15, 16 and 17.
20. **(Original)** The composition of claim 10, comprising an aptamer selected from the group consisting of ARC123, ARC124, ARC125, ARC126, ARC127, and ARC128.
21. **(Original)** An aptamer therapeutic for treatment of diseases of the eye, said aptamer having binding specificity to transforming growth factor beta 2 (TGF β 2), wherein said binding of the aptamer to the TGF β 2 substantially reduces the effect of TGF β 2 in cell proliferation in eye disease states.
22. **(Original)** An aptamer therapeutic for treatment of diseases of the eye, said aptamer having binding specificity to transforming growth factor beta 2 (TGF β 2), wherein said binding of the aptamer to the TGF β 2 substantially reduces the effect of TGF β 2 in post-surgical scarring.

23. **(Original)** An aptamer therapeutic for treatment of diseases of the eye, said aptamer having binding specificity to platelet-derived growth factor, wherein said binding of the aptamer to the platelet-derived growth factor substantially reduces the effect of platelet-derived growth factor in cell proliferation in eye disease states.
24. **(Original)** An aptamer therapeutic for treatment of diseases of the eye, said aptamer having binding specificity to platelet-derived growth factor, wherein said binding of the aptamer to the platelet-derived growth factor substantially reduces the effect of platelet-derived growth factor in post-surgical scarring.
25. **(Withdrawn)** A method of treating a cell proliferation disorder of the eye comprising the step of administering to a patient a therapeutically effective amount of an aptamer therapeutic, said aptamer having binding specificity to a target involved in said disorder, wherein said binding of the aptamer to the target substantially reduces the effect of the target in cell proliferation in the eye disorder.
26. **(Withdrawn)** The method of claim 25, wherein said target is selected from the group consisting of cytokines, growth factors, and cell surface proteins.
27. **(Withdrawn)** The method of claim 26, wherein said target is selected from the group consisting of transforming growth factor beta, platelet-derived growth factor, intracellular adhesion molecule-1, insulin-like growth factor-1, vascular endothelial growth factor, tumor necrosis factor alpha, and integrin alpha 5 beta 3.
28. **(Withdrawn)** The method of claim 25, wherein said aptamer therapeutic is administered to the ocular cavity.

29. **(Withdrawn)** The method of claim 25, wherein said aptamer therapeutic is administered by intravitreal injection.
30. **(Withdrawn)** The method of claim 25, wherein said aptamer therapeutic is administered by subconjunctival injection.
31. **(Withdrawn)** The method of claim 25, wherein said aptamer therapeutic is administered topically.
32. **(Currently Amended)** ~~The composition of claim 1 wherein said aptamer of claim 1,~~
wherein the aptamer is further modified to comprise at least one chemical modification has
~~been modified to increase its stability in aqueous humor present in the eye.~~
33. **(Currently Amended)** ~~The composition aptamer of claim 32, wherein said aptamer-~~
~~comprises modified nucleotides~~ modification is selected from the group consisting of a
chemical substitution at a sugar position, a chemical substitution at a phosphate position,
and a chemical substitution at a base position of the nucleic acid.
34. **(Currently Amended)** The composition of claim [[32]] 1, wherein said aptamer further comprises a polyalkylene glycol moiety.
35. **(Original)** The composition of claim 34, wherein the polyalkylene glycol moiety is a polyethylene glycol.
36. **(Withdrawn)** The composition of claim 34, wherein said aptamer further comprises modified nucleotides.

37. **(Original)** The composition of claim 13, wherein the first and second aptamers are linked by a polyethylene glycol moiety, and further wherein the primary structure of the aptamer composition comprises a linear arrangement in which the first aptamer is linked to a first terminus of the PEG linking moiety and the second aptamer is linked to a second terminus of the PEG linking moiety.
38. **(Original)** The composition of claim 37, wherein the first aptamer is further linked to a terminal polyethylene glycol moiety, wherein the primary structure of the aptamer composition comprises a linear arrangement of polyethylene glycol- first aptamer- polyethylene glycol-second aptamer.
39. **(Original)** An aptamer composition comprising a sequence selected from the group consisting of SEQ ID NO: 1-27, 33-150 and 151.
40. **(New)** The composition of claim 32, wherein said aptamer further comprises a polyalkylene glycol moiety.
41. **(New)** The composition of claim 40, wherein the polyalkylene glycol moiety is a polyethylene glycol.